Literature DB >> 28470667

Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobiotics.

Toshihiro Tanaka1, Weici Zhang1, Ying Sun2, Zongwen Shuai3, Asiya Seema Chida4, Thomas P Kenny1, Guo-Xiang Yang1, Ignacio Sanz4, Aftab Ansari5, Christopher L Bowlus6, Gregory C Ippolito7, Ross L Coppel8, Kazuichi Okazaki9, Xiao-Song He1, Patrick S C Leung1, M Eric Gershwin1.   

Abstract

A major problem in autoimmunity has been identification of the earliest events that lead to breach of tolerance. Although there have been major advances in dissecting effector pathways and the multilineage immune responses to mitochondrial self-antigens in primary biliary cholangitis, the critical links between environmental factors and tolerance remain elusive. We hypothesized that environmental xenobiotic modification of the E2 subunit of the pyruvate dehydrogenase (PDC-E2) inner lipoyl domain can lead to loss of tolerance to genetically susceptible hosts. Previously we demonstrated that serum anti-PDC-E2 autoantibodies cross-react with the chemical xenobiotics 2-octynoic acid and 6,8-bis (acetylthio) octanoic acid and further that there is a high frequency of PDC-E2-specific peripheral plasmablasts. Herein we generated 104 recombinant monoclonal antibodies (mAbs) based on paired heavy-chain and light-chain variable regions of individual plasmablasts derived from primary biliary cholangitis patients. We identified 32 mAbs reactive with native PDC-E2, including 20 specific for PDC-E2 and 12 cross-reactive with both PDC-E2 and 2-octynoic acid and 6,8-bis (acetylthio) octanoic acid. A lower frequency of replacement somatic hypermutations, indicating a lower level of affinity maturation, was observed in the complementarity-determining regions of the cross-reactive mAbs in comparison to mAbs exclusively recognizing PDC-E2 or those for irrelevant antigens. In particular, when the highly mutated heavy-chain gene of a cross-reactive mAb was reverted to the germline sequence, the PDC-E2 reactivity was reduced dramatically, whereas the xenobiotic reactivity was retained. Importantly, cross-reactive mAbs also recognized lipoic acid, a mitochondrial fatty acid that is covalently bound to PDC-E2.
CONCLUSION: Our data reflect that chemically modified lipoic acid or lipoic acid itself, through molecular mimicry, is the initial target that leads to the development of primary biliary cholangitis. (Hepatology 2017;66:885-895).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28470667      PMCID: PMC5570636          DOI: 10.1002/hep.29245

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  37 in total

Review 1.  Competence and competition: the challenge of becoming a long-lived plasma cell.

Authors:  Andreas Radbruch; Gwendolin Muehlinghaus; Elke O Luger; Ayako Inamine; Kenneth G C Smith; Thomas Dörner; Falk Hiepe
Journal:  Nat Rev Immunol       Date:  2006-09-15       Impact factor: 53.106

2.  Microbiomic and Posttranslational Modifications as Preludes to Autoimmune Diseases.

Authors:  Ghislain Opdenakker; Paul Proost; Jo Van Damme
Journal:  Trends Mol Med       Date:  2016-08-02       Impact factor: 11.951

3.  Electrophile-modified lipoic derivatives of PDC-E2 elicits anti-mitochondrial antibody reactivity.

Authors:  Phornnop Naiyanetr; Jeffrey D Butler; Liping Meng; Janice Pfeiff; Thomas P Kenny; Kathryn G Guggenheim; Roman Reiger; Kit Lam; Mark J Kurth; Aftab A Ansari; Ross L Coppel; Marcos López-Hoyos; M Eric Gershwin; Patrick S C Leung
Journal:  J Autoimmun       Date:  2011-07-18       Impact factor: 7.094

4.  Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis.

Authors:  Brian K Chung; Bardia T Guevel; Gary M Reynolds; D B R K Gupta Udatha; Eva Kristine Klemsdal Henriksen; Zania Stamataki; Gideon M Hirschfield; Tom Hemming Karlsen; Evaggelia Liaskou
Journal:  J Autoimmun       Date:  2016-10-24       Impact factor: 7.094

5.  Autoantibodies to BCOADC-E2 in patients with primary biliary cirrhosis recognize a conformational epitope.

Authors:  P S Leung; D T Chuang; R M Wynn; S Cha; D J Danner; A Ansari; R L Coppel; M E Gershwin
Journal:  Hepatology       Date:  1995-08       Impact factor: 17.425

6.  High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires.

Authors:  Evaggelia Liaskou; Eva Kristine Klemsdal Henriksen; Kristian Holm; Fatemeh Kaveh; David Hamm; Janine Fear; Marte K Viken; Johannes Roksund Hov; Espen Melum; Harlan Robins; Johanna Olweus; Tom H Karlsen; Gideon M Hirschfield
Journal:  Hepatology       Date:  2015-09-30       Impact factor: 17.425

7.  Molecular basis of 9G4 B cell autoreactivity in human systemic lupus erythematosus.

Authors:  Christopher Richardson; Asiya Seema Chida; Diana Adlowitz; Lin Silver; Erin Fox; Scott A Jenks; Elise Palmer; Youliang Wang; Jamie Heimburg-Molinaro; Quan-Zhen Li; Chandra Mohan; Richard Cummings; Christopher Tipton; Ignacio Sanz
Journal:  J Immunol       Date:  2013-10-09       Impact factor: 5.422

8.  Systems biology of vaccination for seasonal influenza in humans.

Authors:  Helder I Nakaya; Jens Wrammert; Eva K Lee; Luigi Racioppi; Stephanie Marie-Kunze; W Nicholas Haining; Anthony R Means; Sudhir P Kasturi; Nooruddin Khan; Gui-Mei Li; Megan McCausland; Vibhu Kanchan; Kenneth E Kokko; Shuzhao Li; Rivka Elbein; Aneesh K Mehta; Alan Aderem; Kanta Subbarao; Rafi Ahmed; Bali Pulendran
Journal:  Nat Immunol       Date:  2011-07-10       Impact factor: 25.606

9.  Long-lived antigen-induced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection.

Authors:  Caitlin Bohannon; Ryan Powers; Lakshmipriyadarshini Satyabhama; Ang Cui; Christopher Tipton; Miri Michaeli; Ioanna Skountzou; Robert S Mittler; Steven H Kleinstein; Ramit Mehr; Frances Eun-Yun Lee; Ignacio Sanz; Joshy Jacob
Journal:  Nat Commun       Date:  2016-06-07       Impact factor: 14.919

10.  The autoepitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase.

Authors:  J Van de Water; M E Gershwin; P Leung; A Ansari; R L Coppel
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Environmental basis of primary biliary cholangitis.

Authors:  Atsushi Tanaka; Patrick Sc Leung; M Eric Gershwin
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-07

Review 2.  Pathogen infections and primary biliary cholangitis.

Authors:  A Tanaka; P S C Leung; M E Gershwin
Journal:  Clin Exp Immunol       Date:  2018-09-17       Impact factor: 4.330

Review 3.  Primary biliary cholangitis: a comprehensive overview.

Authors:  Ana Lleo; Simona Marzorati; Juan-Manuel Anaya; M Eric Gershwin
Journal:  Hepatol Int       Date:  2017-11-21       Impact factor: 6.047

Review 4.  Chronic Autoimmune Epithelitis in Sjögren's Syndrome and Primary Biliary Cholangitis: A Comprehensive Review.

Authors:  Carlo Selmi; M Eric Gershwin
Journal:  Rheumatol Ther       Date:  2017-08-08

5.  Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes.

Authors:  Irina Tsymala; Magdalini Nigritinou; Bleranda Zeka; Rouven Schulz; Felix Niederschick; Mia Matković; Isabel J Bauer; Michael Szalay; Kathrin Schanda; Magdalena Lerch; Tatsuro Misu; Kazuo Fujihara; Jeffrey L Bennett; Charlotte Dahle; Florence Pache; Paulus Rommer; Fritz Leutmezer; Zsolt Illes; Maria Isabel Leite; Jacqueline Palace; Petra Scholze; Markus Reindl; Hans Lassmann; Monika Bradl
Journal:  Acta Neuropathol Commun       Date:  2020-04-15       Impact factor: 7.801

6.  Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not Due to Anti-mitochondrial Antibodies.

Authors:  Isabell Nilsson; Jeremy Palmer; Eirini Apostolou; Carl-Gerhard Gottfries; Muhammad Rizwan; Charlotte Dahle; Anders Rosén
Journal:  Front Med (Lausanne)       Date:  2020-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.